<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To report a case of <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> (PTC) following treatment with human recombinant growth hormone (GH) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A 42-year-old man who developed <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> 7 years after starting human recombinant GH treatment is presented </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: The patient's medical history was significant for hypophyseal <z:hpo ids='HP_0003510'>dwarfism</z:hpo> with a serious deficit of GH, hypogonadotropic <z:hpo ids='HP_0000135'>hypogonadism</z:hpo>, and <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>In 1996 he started taking GH, <z:chebi fb="51" ids="17347">testosterone</z:chebi>, and <z:chebi fb="0" ids="18332">L-thyroxine</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Fundus examination showed disc <z:hpo ids='HP_0000969'>edema</z:hpo> in the left eye </plain></SENT>
<SENT sid="5" pm="."><plain>GH was discontinued, and <z:chebi fb="0" ids="27690">acetazolamide</z:chebi> therapy was initiated </plain></SENT>
<SENT sid="6" pm="."><plain>At the 3-month follow-up the acuity without correction was patch and the unilateral <z:hpo ids='HP_0001085'>papilledema</z:hpo> had resolved </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">Pseudotumor cerebri</z:e> or idiopathic intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> is an uncommon and complex disorder </plain></SENT>
<SENT sid="8" pm="."><plain>The diagnosis is possible when important criteria symptoms and signs are met </plain></SENT>
<SENT sid="9" pm="."><plain>Several conditions and risk factors are associated with PTC </plain></SENT>
<SENT sid="10" pm="."><plain>The most recently recognized risk factor is GH therapy </plain></SENT>
</text></document>